Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety.
Kineta, Inc. (NASDAQ:KA – Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 75,300 shares, a growth of 276.5% from the February 29th total of 20,000 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average trading volume of […]
Kineta, Inc. (NASDAQ:KA – Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 44,700 shares, a decline of 13.4% from the November 30th total of 51,600 shares. Approximately 0.6% of the shares of the stock are short […]
Kineta, Inc. (NASDAQ:KA – Get Free Report) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 61,300 shares, a decline of 39.1% from the October 31st total of 100,700 shares. Approximately 0.9% of the shares of the stock are sold […]
Kineta (NASDAQ:KA – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09, reports. Kineta Stock Up 5.7 % Shares of KA traded up $0.24 during trading hours on Monday, hitting $4.42. 44,832 shares of the […]